Last 20 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -28.27 | — | — | — | — | — | — | — | — | 36.51 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 302.09 | 554.89 | 234.68 | 122.52 | 111.48 | 67.43 | 43.17 | 26.96 | 23.37 | 11.49 | 29.05 | 26.59 | 20.11 | — | — | — | — | — | — | — | — |
| — | +722.9% | +443.7% | +354.4% | +377.1% | +487.0% | +48.6% | +1.4% | +16.2% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 16.10 | 9.12 | 10.54 | 9.44 | 8.69 | 9.05 | 9.31 | 6.06 | 7.39 | 5.98 | 6.53 | 5.18 | 4.74 | 6.67 | 3.48 | 2.09 | 1.31 | — | — | — | — |
| — | +0.8% | +13.3% | +55.7% | +17.7% | +51.5% | +42.5% | +17.0% | +55.7% | -10.3% | +87.6% | +147.3% | +261.2% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | 39.53 | — | — | 13.70 | — | — | 1.99 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 41.42 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 30.37 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.0% | 0.8% | -609.0% | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% | 97.9% | 98.9% | 97.0% | 95.1% | 95.9% | — | — | — | — | — | — | — | — |
| — | -99.2% | -709.0% | +4.7% | +2.1% | +1.2% | +3.1% | +0.4% | +2.1% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1135.6% | -3850.2% | -1248.3% | -777.4% | -847.6% | -348.2% | -129.1% | -127.8% | -40.3% | 23.8% | -299.9% | -206.7% | -170.0% | — | — | — | — | — | — | — | — |
| — | -1005.8% | -866.6% | -508.4% | -2004.5% | -1565.9% | +56.9% | +38.2% | +76.3% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1027.3% | -3513.4% | -1127.1% | -698.6% | -766.0% | -308.4% | -99.4% | -99.3% | -18.3% | 31.4% | -263.0% | -166.8% | -152.7% | — | — | — | — | — | — | — | — |
| — | -1039.2% | -1034.2% | -603.3% | -4077.7% | -1081.4% | +62.2% | +40.4% | +88.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.4% | -13.8% | -13.4% | -13.0% | -14.3% | -10.0% | -5.3% | -5.5% | -1.5% | 5.3% | -14.1% | -8.0% | -10.8% | -17.7% | -33.6% | -11.4% | -52.0% | — | — | -22.3% | -18.0% |
| — | -37.3% | -151.2% | -135.9% | -874.5% | -290.1% | +62.1% | +30.8% | +86.4% | +129.9% | +58.2% | +30.2% | +79.3% | — | — | +48.7% | -189.3% | — | — | — | — | |
| ROA | -34.8% | -9.2% | -8.7% | -8.3% | -9.2% | -6.4% | -3.5% | -3.6% | -0.9% | 2.8% | -6.4% | -3.8% | -5.8% | -12.0% | -26.1% | -9.9% | -14.0% | -15.1% | -11.8% | — | -15.8% |
| — | -44.6% | -153.6% | -131.8% | -921.3% | -331.3% | +45.7% | +6.1% | +84.6% | +123.0% | +75.6% | +61.5% | +58.3% | +20.7% | -121.1% | — | +11.2% | — | — | — | — | |
| ROIC | -46.2% | -11.5% | -11.6% | -11.4% | -13.0% | -10.1% | -5.9% | -5.9% | -3.8% | 5.1% | -20.2% | -22.2% | -13.2% | -12.1% | -31.5% | -16.7% | — | — | — | -16.7% | — |
| — | -13.7% | -95.8% | -93.7% | -239.7% | -296.2% | +70.6% | +73.4% | +71.0% | +142.5% | +35.7% | -32.5% | — | — | — | +0.1% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.12 | 0.13 | 0.13 | 0.12 | 0.14 | 0.15 | 0.18 | 0.20 | 0.41 | 0.32 | 0.29 | 0.43 | 0.37 | 0.09 | 0.02 | — | — | — | — |
| — | +101.2% | -13.1% | -12.2% | -27.5% | -40.9% | -66.9% | -52.2% | -39.0% | -53.2% | +11.1% | +241.3% | +1126.5% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 6.21 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.44 | 4.44 | 3.99 | 3.81 | 4.93 | 4.78 | 4.29 | 6.01 | 5.46 | 6.06 | 2.84 | 3.57 | 3.44 | 4.71 | 6.48 | 10.16 | 13.14 | 7.60 | 10.12 | — | 9.36 |
| — | -7.2% | -7.0% | -36.6% | -9.7% | -21.1% | +51.0% | +68.0% | +58.6% | +28.7% | -56.2% | -64.8% | -73.8% | -38.1% | -35.9% | — | +40.4% | — | — | — | — | |
| Quick Ratio | 4.44 | 4.44 | 3.99 | 3.81 | 4.93 | 4.78 | 4.29 | 6.01 | 5.46 | 6.06 | 2.84 | 3.57 | 3.44 | 4.71 | 6.48 | 10.16 | 13.14 | 7.60 | 10.12 | — | 9.36 |
| — | -7.2% | -7.0% | -36.6% | -9.7% | -21.1% | +51.0% | +68.0% | +58.6% | +28.7% | -56.2% | -64.8% | -73.8% | -38.1% | -35.9% | — | +40.4% | — | — | — | — | |
| Interest Coverage | -8.45 | -1.40 | — | — | -5188.17 | -6509.86 | -223.95 | -82.68 | -11.24 | 21.95 | -40.02 | -26.43 | -25.33 | -8.30 | -154.83 | -10256.33 | -6509.25 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 20 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACLX stock.
Arcellx, Inc.'s current P/E is -28.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arcellx, Inc.'s current operating margin is -1135.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arcellx, Inc.'s business trajectory between earnings reports.